Literature DB >> 7923682

Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits.

S Ameli1, A Hultgardh-Nilsson, B Cercek, P K Shah, J S Forrester, H Ageland, J Nilsson.   

Abstract

BACKGROUND: Several epidemiological studies have shown an inverse relation between high-density lipoprotein (HDL) cholesterol levels and coronary heart disease. Recently, observational studies have suggested a similar inverse relation between HDL and restenosis after coronary balloon angioplasty. Despite these observations, it is unclear whether this inverse relation reflects a direct vascular protective effect of HDL or apolipoprotein (apo) A-I, the major apolipoprotein component of HDL. Therefore, to determine whether HDL directly influences neointima formation, we investigated the effect of recombinant apo A-I Milano (apo A-I M), a mutant of human apo A-I with Arg-173 to Cys substitution, on intimal thickening after balloon injury in cholesterol-fed rabbits. METHODS AND
RESULTS: Cholesterol feeding was initiated 18 days before injury and continued until the time of death. Eight rabbits received intravenous injections of 40 mg of apo A-I M linked to a phospholipid carrier on alternate days, beginning 5 days before and continuing for 5 days after balloon injury of femoral and iliac arteries. Eight rabbits received the carrier alone, and four received neither apo A-I M nor the carrier. Three weeks after balloon injury, apo A-I M-treated rabbits had significantly reduced intimal thickness compared with the two control groups (mean +/- SD): 0.49 +/- 0.29 versus 1.14 +/- 0.38 mm2 and 1.69 +/- 0.43 mm2, P < .002 by ANOVA). The intima-to-media ratio was also significantly reduced by apo A-I M (0.7 +/- 0.2 versus 1.5 +/- 0.5 and 2.1 +/- 0.1, P < .002 by ANOVA) compared with the two controls. The fraction of intimal lesion covered by macrophages, as identified by immunohistochemistry using macrophage-specific monoclonal antibody, was significantly less in apo A-I M-treated rabbits compared with carrier-treated animals (25.3 +/- 17% versus 59.4 +/- 12.3%, P < .005). Aortic cholesterol content, measured in an additional 10 rabbits, did not differ significantly between apo A-I M-treated animals (n = 5) and carrier-treated controls (n = 5).
CONCLUSIONS: Apo A-I M significantly reduced intimal thickening and macrophage content after balloon injury in cholesterol-fed rabbits without a change in arterial total cholesterol content. Although the precise mechanism of action remains to be defined, these findings are consistent with a direct vascular effect of apo A-I, which could have potential therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923682     DOI: 10.1161/01.cir.90.4.1935

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  39 in total

Review 1.  Therapeutic strategies to deplete macrophages in atherosclerotic plaques.

Authors:  Inge De Meyer; Wim Martinet; Guido R Y De Meyer
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

Review 2.  The paraoxonase gene family and atherosclerosis.

Authors:  David Seo; Pascal Goldschmidt-Clermont
Journal:  Curr Atheroscler Rep       Date:  2009-05       Impact factor: 5.113

Review 3.  Pharmacomodulation of high-density lipoprotein metabolism as a therapeutic intervention for atherosclerotic disease.

Authors:  Peter P Toth
Journal:  Curr Cardiol Rep       Date:  2010-11       Impact factor: 2.931

Review 4.  Novel HDL-directed pharmacotherapeutic strategies.

Authors:  Emil M Degoma; Daniel J Rader
Journal:  Nat Rev Cardiol       Date:  2011-01-18       Impact factor: 32.419

Review 5.  Apo a-I modulating therapies.

Authors:  Stephen J Nicholls
Journal:  Curr Cardiol Rep       Date:  2011-12       Impact factor: 2.931

6.  Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice.

Authors:  Lai Wang; Behrooz G Sharifi; Theresa Pan; Lei Song; Ada Yukht; Prediman K Shah
Journal:  J Am Coll Cardiol       Date:  2006-08-28       Impact factor: 24.094

7.  Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo.

Authors:  Frank M Sacks; Lawrence L Rudel; Adam Conner; Hassibullah Akeefe; Gerhard Kostner; Talal Baki; George Rothblat; Margarita de la Llera-Moya; Bela Asztalos; Timothy Perlman; Chunyu Zheng; Petar Alaupovic; Jo-Ann B Maltais; H Bryan Brewer
Journal:  J Lipid Res       Date:  2009-01-14       Impact factor: 5.922

8.  An apoA-I mimetic peptide facilitates off-loading cholesterol from HDL to liver cells through scavenger receptor BI.

Authors:  Xuelei Song; Paul Fischer; Xun Chen; Charlotte Burton; Jun Wang
Journal:  Int J Biol Sci       Date:  2009-10-09       Impact factor: 6.580

9.  Impact of medical therapy on atheroma volume measured by different cardiovascular imaging modalities.

Authors:  Mohamad C N Sinno; Mouaz Al-Mallah
Journal:  Cardiol Res Pract       Date:  2010-07-01       Impact factor: 1.866

10.  An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration.

Authors:  Xun Chen; Charlotte Burton; Xuelei Song; Lesley McNamara; Annunziata Langella; Simona Cianetti; Ching H Chang; Jun Wang
Journal:  Int J Biol Sci       Date:  2009-07-28       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.